STOCK TITAN

Evoke Pharma Inc - EVOK STOCK NEWS

Welcome to our dedicated news page for Evoke Pharma (Ticker: EVOK), a resource for investors and traders seeking the latest updates and insights on Evoke Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Evoke Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Evoke Pharma's position in the market.

Rhea-AI Summary
Evoke Pharma, Inc. (EVOK) closes a $30 million public offering led by Nantahala Capital Management, with potential for an additional $22.5 million if all warrants are exercised. The company plans to use the funds for working capital, general corporate purposes, and potentially for in-licensing, acquiring, or investing in complementary businesses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.75%
Tags
offering
-
Rhea-AI Summary
Evoke Pharma, Inc. (EVOK) announced an underwritten public offering led by Nantahala Capital Management, raising up to $30 million for working capital and corporate purposes. The offering includes 11,029,411 shares of common stock and warrants, with a combined price per share of $0.68.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.86%
Tags
offering
-
Rhea-AI Summary
Evoke Pharma, Inc. (EVOK) announced that its GIMOTI nasal spray has received a new U.S. patent, No. 11,813,231, listed in the FDA's Orange Book, with coverage until 2029. This adds to the previous three patents, providing enhanced patent protection for GIMOTI. The company aims to redefine gastroparesis treatment with GIMOTI, targeting diabetic gastroparesis and reducing hospitalizations. The patent listing in the Orange Book allows for easier monitoring of potential generic drugs that could infringe on GIMOTI's patents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4%
Tags
none
Rhea-AI Summary
Evoke Pharma, Inc. (NASDAQ: EVOK) announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,813,231 titled “Nasal Formulations of Metoclopramide” for their commercially available and FDA-approved nasal formulation of metoclopramide, GIMOTI. This patent provides additional intellectual property protections and claims to metoclopramide being delivered intranasally. The company sees significant commercial value, especially with the rising popularity of GLP-1 agonist medications for diabetes potentially unmasking gastroparesis in larger patient groups. GIMOTI is the only outpatient, non-oral drug labeled for the treatment of acute and recurrent diabetic gastroparesis, addressing the unpredictability of tablet absorption caused by gastroparesis symptoms. Evoke Pharma aims to continue providing patients with life-changing experiences and enhancing the commercial opportunity for GIMOTI.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.2%
Tags
none
-
Rhea-AI Summary
Evoke Pharma, Inc. (NASDAQ: EVOK) reports a 38% revenue increase compared to Q2 2023 and an 88% increase year-over-year. The company experienced a seventh straight prescription fill increase since Q1 2022, with a 21% increase compared to Q2 2023 and a 95% increase year-over-year. The financial results for the third quarter ended September 30, 2023, show record net product sales of $1.6 million. The company also presented data at the ACG 2023 Annual Meeting demonstrating the superiority of its nasal spray, GIMOTI, in reducing healthcare costs for treating diabetic gastroparesis patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.34%
Tags
earnings
-
Rhea-AI Summary
Evoke Pharma and EVERSANA announced real-world data on the positive impact of GIMOTI nasal spray in reducing healthcare costs for patients with diabetic gastroparesis. Patients and insurers saved over $15,000 per patient in a six-month period by using GIMOTI instead of oral metoclopramide. The study showed a significant reduction in emergency department visits, hospitalizations, and office visits for patients using GIMOTI compared to oral metoclopramide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
none
Rhea-AI Summary
Evoke Pharma to present real-world healthcare utilization data on GIMOTI nasal spray at the American College of Gastroenterology annual meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
none
-
Rhea-AI Summary
Evoke Pharma granted patent for GIMOTI nasal spray, expected to expire in 2029. GIMOTI demonstrates reduction in healthcare resource utilization. GIMOTI can become first-line treatment for diabetic gastroparesis. Commercially available since 2020, prescribed by over a thousand HCPs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.96%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.84%
Tags
none
Evoke Pharma Inc

Nasdaq:EVOK

EVOK Rankings

EVOK Stock Data

5.85M
2.98M
0.97%
0.81%
12.2%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Solana Beach

About EVOK

evoke pharma is a biotechnology company located in 505 lomas santa fe dr, solana beach, california, united states.